Posted by Michael Wonder on 15 Jun 2020
Romosozumab in osteoporosis: considerable added benefit for women after menopause
15 June 2020 - Fewer vertebral fractures and fewer other typical fractures in post-menopausal women with severe osteoporosis at high risk of fracture.
Romosozumab is a bone-forming monoclonal antibody used in women after menopause for the treatment of severe osteoporosis if there is a high risk of bone fractures.
Having been granted approval for this therapeutic indication by the European Medicines Agency in December 2019, it has been available on the German market since March 2020.
